Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Prevention of Growth Failure in Turner Syndrome: Long-Term Results of Early Growth Hormone Treatment in the "toddler Turner" Cohort

  • Charmian A. Quigley
  • , Patricia Y. Fechner
  • , Mitchell E. Geffner
  • , Erica A. Eugster
  • , Judith L. Ross
  • , Reema L. Habiby
  • , Figen Ugrasbul
  • , Karen Rubin
  • , Sharon Travers
  • , Caryl J. Antalis
  • , Hiren N. Patel
  • , Marsha L. Davenport
  • Sydney Children's Hospital
  • Seattle Children's
  • University of Southern California
  • Indiana University Bloomington
  • Thomas Jefferson University
  • Northwestern University
  • Children's Mercy Hospitals and Clinics
  • Connecticut Children's Medical Center
  • Children's Hospital Denver
  • University of Colorado Anschutz Medical Campus
  • Eli Lilly
  • University of North Carolina at Chapel Hill

Producción científicarevisión exhaustiva

26 Citas (Scopus)

Resumen

Introduction: In the randomized "Toddler Turner"study, girls who received growth hormone (GH) starting at ages 9 months to 4 years (early-Treated [ET] group) had marked catch-up growth and were 1.6 ± 0.6 SD taller than untreated (early-untreated [EUT]) control girls after 2 years. However, whether the early catch-up growth would result in greater near-Adult height (NAH) was unknown. Therefore, this extension study examined the long-Term effects of toddler-Age GH treatment on height, pubertal development, and safety parameters. Methods: Toddler Turner study participants were invited to enroll in a 10-year observational extension study for annual assessments of growth, pubertal status, and safety during long-Term GH treatment to NAH for both ET and EUT groups. Results: The ET group was taller than the EUT group at all time points from preschool to maturity and was significantly taller at the onset of puberty (p = 0.016), however, the difference was not significant at NAH. For the full cohort (ET + EUT combined, n = 50) mean (± SD) NAH was 151.2 ± 7.1 cm at age 15.0 ± 1.3 years. NAH standard deviation score (SDS) was within the normal range (-2.0) for 76% of ET and 60% of EUT subjects (68% overall) and correlated strongly with height SDS at GH start (r = 0.78; p 0.01), which in turn had a modest inverse correlation with age at GH start (i.e., height SDS declined with increasing age in untreated girls [r =-0.30; p = 0.016]). No new safety concerns arose. Conclusion: Although the ET group was taller throughout, height SDS at NAH was not significantly different between groups due to catch-down growth of ET girls during lapses in GH treatment after the Toddler study and similar long-Term GH exposure overall. Early initiation of GH by age 6 years, followed by uninterrupted treatment during childhood, can prevent ongoing growth failure and enable attainment of height within the normal range during childhood, adolescence, and adulthood.

Idioma originalEnglish
Páginas (desde-hasta)18-35
Número de páginas18
PublicaciónHormone Research in Paediatrics
Volumen94
N.º1-2
DOI
EstadoPublished - 1 jul 2021
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'Prevention of Growth Failure in Turner Syndrome: Long-Term Results of Early Growth Hormone Treatment in the "toddler Turner" Cohort'. En conjunto forman una huella única.

Citar esto